Dapsone
- PDF / 169,822 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 59 Downloads / 141 Views
1 S
Hypersensitivity syndrome: 7 case reports In a retrospective review of all patients, who received dapsone between 2003 and 2017 at the Seoul National University Hospital and were registered in the Korean Severe Cutaneous Adverse Reactions (SCAR) registry, 7 patients (6 women and 1 boy) aged 11–59 years were described, who developed hypersensitivity syndrome following treatment with dapsone. The patients started receiving dapsone [routes and dosages not stated] for acne vulgaris, allergic cutaneous vasculitis, contact dermatitis, folliculitis, IgA bullous dermatosis, parapsoriasis and prurigo pigmentosa (1 patient each). However, after 14–42 days, all patients developed dapsone hypersensitivity syndrome, which manifested in the form of a fever, accompanied by elevated levels of eosinophils, leucocytes and ALT, with 50–100% skin involvement of total body surface area. Six patients also exhibited atypical lymphocytes; two of these patients additionally exhibited low platelet levels, whereas 2 patients, including 1 patient, who exhibited low platelet levels, exhibited elevated creatinine levels, while the other one of these 2 patients additionally experienced an infectious mononucleosis-like syndrome. All patients were subsequently hospitalised. All patients received unspecified systemic steroids and remained hospitalised for 12–60 days. None of the patients died [outcomes not stated]. Park HJ, et al. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses. Expert Opinion on Drug Safety : 803500781 18 Aug 2020. Available from: URL: http://doi.org/10.1080/14740338.2020.1796965
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
